Janssen Says In Additional Datasets, Tremfya Showed Rapid & Significant Scalp Psoriasis Clearance And Improved Key Health-Related Quality Of Life Outcomes
Portfolio Pulse from Benzinga Newsdesk
Janssen, a pharmaceutical company of Johnson & Johnson (JNJ), announced that additional datasets showed its drug Tremfya had rapid and significant effects in clearing scalp psoriasis and improving key health-related quality of life outcomes.
October 20, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive results from Janssen's Tremfya could potentially boost Johnson & Johnson's stock in the short term.
The positive results from Janssen's Tremfya could potentially boost Johnson & Johnson's stock in the short term as it indicates the company's strong product pipeline and potential for increased revenues from the drug.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100